In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Arcus Biosciences trades at $30, substantially above its PERT-weighted fair value of $13.86, indicating an overvaluation risk of -53.8%. High liquidity and leverage contrast with zero profitability and efficiency, reflecting financial strain despite strong cash position. Monte Carlo analysis shows negligible downside below current price, suggesting price may reflect market optimism more than fundamentals.